Allison W Kurian1, Kevin C Ward2, Paul Abrahamse3, Irina Bondarenko3, Ann S Hamilton4, Dennis Deapen4, Monica Morrow5, Jonathan S Berek6, Timothy P Hofer7, Steven J Katz3. 1. Departments of Medicine and of Epidemiology & Population Health, Stanford University, Stanford, CA. 2. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA. 3. Department of Health Management and Policy, School of Public Health, Department of Biostatistics, University of Michigan, Ann Arbor, MI. 4. Department of Preventive Medicine in the Keck School of Medicine, University of Southern California, Los Angeles, CA. 5. Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY. 6. Department of Obstetrics and Gynecology and Women's Cancer Center, Stanford University, Stanford, CA. 7. Department of Internal Medicine, University of Michigan and Center for Clinical Management Research, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI.
Abstract
PURPOSE: Genetic testing is important for breast and ovarian cancer risk reduction and treatment, yet little is known about its evolving use. METHODS: SEER records of women of age ≥ 20 years diagnosed with breast or ovarian cancer from 2013 to 2017 in California or Georgia were linked to the results of clinical germline testing through 2019. We measured testing trends, rates of variants of uncertain significance (VUS), and pathogenic variants (PVs). RESULTS: One quarter (25.2%) of 187,535 patients with breast cancer and one third (34.3%) of 14,689 patients with ovarian cancer were tested; annually, testing increased by 2%, whereas the number of genes tested increased by 28%. The prevalence of test results by gene category for breast cancer cases in 2017 were BRCA1/2, PVs 5.2%, and VUS 0.8%; breast cancer-associated genes or ovarian cancer-associated genes (ATM, BARD1, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, NF1, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, and TP53), PVs 3.7%, and VUS 12.0%; other actionable genes (APC, BMPR1A, MEN1, MUTYH, NF2, RB1, RET, SDHAF2, SDHB, SDHC, SDHD, SMAD4, TSC1, TSC2, and VHL) PVs 0.6%, and VUS 0.5%; and other genes, PVs 0.3%, and VUS 2.6%. For ovarian cancer cases in 2017, the prevalence of test results were BRCA1/2, PVs 11.0%, and VUS 0.9%; breast or ovarian genes, PVs 4.0%, and VUS 12.6%; other actionable genes, PVs 0.7%, and VUS 0.4%; and other genes, PVs 0.3%, and VUS 0.6%. VUS rates doubled over time (2013 diagnoses: 11.2%; 2017 diagnoses: 26.8%), particularly for racial or ethnic minorities (47.8% Asian and 46.0% Black, v 24.6% non-Hispanic White patients; P < .001). CONCLUSION: A testing gap persists for patients with ovarian cancer (34.3% tested v nearly all recommended), whereas adding more genes widened a racial or ethnic gap in VUS results. Most PVs were in 20 breast cancer-associated genes or ovarian cancer-associated genes; testing other genes yielded mostly VUS. Quality improvement should focus on testing indicated patients rather than adding more genes.
PURPOSE: Genetic testing is important for breast and ovarian cancer risk reduction and treatment, yet little is known about its evolving use. METHODS: SEER records of women of age ≥ 20 years diagnosed with breast or ovarian cancer from 2013 to 2017 in California or Georgia were linked to the results of clinical germline testing through 2019. We measured testing trends, rates of variants of uncertain significance (VUS), and pathogenic variants (PVs). RESULTS: One quarter (25.2%) of 187,535 patients with breast cancer and one third (34.3%) of 14,689 patients with ovarian cancer were tested; annually, testing increased by 2%, whereas the number of genes tested increased by 28%. The prevalence of test results by gene category for breast cancer cases in 2017 were BRCA1/2, PVs 5.2%, and VUS 0.8%; breast cancer-associated genes or ovarian cancer-associated genes (ATM, BARD1, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, NF1, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, and TP53), PVs 3.7%, and VUS 12.0%; other actionable genes (APC, BMPR1A, MEN1, MUTYH, NF2, RB1, RET, SDHAF2, SDHB, SDHC, SDHD, SMAD4, TSC1, TSC2, and VHL) PVs 0.6%, and VUS 0.5%; and other genes, PVs 0.3%, and VUS 2.6%. For ovarian cancer cases in 2017, the prevalence of test results were BRCA1/2, PVs 11.0%, and VUS 0.9%; breast or ovarian genes, PVs 4.0%, and VUS 12.6%; other actionable genes, PVs 0.7%, and VUS 0.4%; and other genes, PVs 0.3%, and VUS 0.6%. VUS rates doubled over time (2013 diagnoses: 11.2%; 2017 diagnoses: 26.8%), particularly for racial or ethnic minorities (47.8% Asian and 46.0% Black, v 24.6% non-Hispanic White patients; P < .001). CONCLUSION: A testing gap persists for patients with ovarian cancer (34.3% tested v nearly all recommended), whereas adding more genes widened a racial or ethnic gap in VUS results. Most PVs were in 20 breast cancer-associated genes or ovarian cancer-associated genes; testing other genes yielded mostly VUS. Quality improvement should focus on testing indicated patients rather than adding more genes.
Authors: Andrea Desmond; Allison W Kurian; Michele Gabree; Meredith A Mills; Michael J Anderson; Yuya Kobayashi; Nora Horick; Shan Yang; Kristen M Shannon; Nadine Tung; James M Ford; Stephen E Lincoln; Leif W Ellisen Journal: JAMA Oncol Date: 2015-10 Impact factor: 31.777
Authors: Samir Gupta; Dawn Provenzale; Scott E Regenbogen; Heather Hampel; Thomas P Slavin; Michael J Hall; Xavier Llor; Daniel C Chung; Dennis J Ahnen; Travis Bray; Gregory Cooper; Dayna S Early; James M Ford; Francis M Giardiello; William Grady; Amy L Halverson; Stanley R Hamilton; Jason B Klapman; David W Larson; Audrey J Lazenby; Patrick M Lynch; Arnold J Markowitz; Robert J Mayer; Reid M Ness; Niloy Jewel Samadder; Moshe Shike; Shajanpeter Sugandha; Jennifer M Weiss; Mary A Dwyer; Ndiya Ogba Journal: J Natl Compr Canc Netw Date: 2017-12 Impact factor: 11.908
Authors: Allison W Kurian; Kevin C Ward; Ann S Hamilton; Dennis M Deapen; Paul Abrahamse; Irina Bondarenko; Yun Li; Sarah T Hawley; Monica Morrow; Reshma Jagsi; Steven J Katz Journal: JAMA Oncol Date: 2018-08-01 Impact factor: 31.777
Authors: Mansoor R Mirza; Bradley J Monk; Jørn Herrstedt; Amit M Oza; Sven Mahner; Andrés Redondo; Michel Fabbro; Jonathan A Ledermann; Domenica Lorusso; Ignace Vergote; Noa E Ben-Baruch; Christian Marth; Radosław Mądry; René D Christensen; Jonathan S Berek; Anne Dørum; Anna V Tinker; Andreas du Bois; Antonio González-Martín; Philippe Follana; Benedict Benigno; Per Rosenberg; Lucy Gilbert; Bobbie J Rimel; Joseph Buscema; John P Balser; Shefali Agarwal; Ursula A Matulonis Journal: N Engl J Med Date: 2016-10-07 Impact factor: 91.245
Authors: Jonathan Ledermann; Philipp Harter; Charlie Gourley; Michael Friedlander; Ignace Vergote; Gordon Rustin; Clare Scott; Werner Meier; Ronnie Shapira-Frommer; Tamar Safra; Daniela Matei; Euan Macpherson; Claire Watkins; James Carmichael; Ursula Matulonis Journal: N Engl J Med Date: 2012-03-27 Impact factor: 91.245
Authors: Talia Golan; Pascal Hammel; Michele Reni; Eric Van Cutsem; Teresa Macarulla; Michael J Hall; Joon-Oh Park; Daniel Hochhauser; Dirk Arnold; Do-Youn Oh; Anke Reinacher-Schick; Giampaolo Tortora; Hana Algül; Eileen M O'Reilly; David McGuinness; Karen Y Cui; Katia Schlienger; Gershon Y Locker; Hedy L Kindler Journal: N Engl J Med Date: 2019-06-02 Impact factor: 91.245
Authors: Julie R Palmer; Eric C Polley; Chunling Hu; Esther M John; Christopher Haiman; Steven N Hart; Mia Gaudet; Tuya Pal; Hoda Anton-Culver; Amy Trentham-Dietz; Leslie Bernstein; Christine B Ambrosone; Elisa V Bandera; Kimberly A Bertrand; Traci N Bethea; Chi Gao; Rohan D Gnanaolivu; Hongyan Huang; Kun Y Lee; Loic LeMarchand; Jie Na; Dale P Sandler; Payal D Shah; Siddhartha Yadav; William Yang; Jeffrey N Weitzel; Susan M Domchek; David E Goldgar; Katherine L Nathanson; Peter Kraft; Song Yao; Fergus J Couch Journal: J Natl Cancer Inst Date: 2020-12-14 Impact factor: 13.506
Authors: Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm Journal: Genet Med Date: 2015-03-05 Impact factor: 8.822
Authors: Allison W Kurian; Paul Abrahamse; Kevin C Ward; Ann S Hamilton; Dennis Deapen; Jonathan S Berek; Lily Hoang; Amal Yussuf; Jill Dolinsky; Krystal Brown; Thomas Slavin; Timothy P Hofer; Steven J Katz Journal: JCO Precis Oncol Date: 2021-12-22
Authors: Stacy W Gray; Rebecca A Ottesen; Madeline Currey; Mihaela Cristea; Janet Nikowitz; Susan Shehayeb; Vanessa Lozano; Julie Hom; Julie Kilburn; Lisa N Lopez; Sam Wing; Ernesto Sosa; Jenny Shen; Michael Morris; Bedros Dilsizian; Thomas Joseph; James Shen; Camille Adeimy; Tanyanika Phillips; Bahareh Bahadini; Joyce C Niland Journal: JCO Clin Cancer Inform Date: 2022-09
Authors: Allison W Kurian; Paul Abrahamse; Irina Bondarenko; Ann S Hamilton; Dennis Deapen; Scarlett L Gomez; Monica Morrow; Jonathan S Berek; Timothy P Hofer; Steven J Katz; Kevin C Ward Journal: J Natl Cancer Inst Date: 2022-02-07 Impact factor: 11.816